Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Indomethacin vs Stent + Indomethacin for PEP Prevention
NCT05857514Unknown
- Sponsor
- Motilal Nehru Medical College
- Start
- May 2023
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of indomethacin in post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP) (2 arms), sponsored by Motilal Nehru Medical College. Primary endpoint: Incidence of post-ERCP pancreatitis at 24 hours. Status: unknown.
02
Drugs
indomethacin
03
Conditions
post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP)
Beyond the preview
Go deeper on NCT05857514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05857514.